RU2613324C3 - Композиция для контролируемой стимуляции яичников - Google Patents
Композиция для контролируемой стимуляции яичниковInfo
- Publication number
- RU2613324C3 RU2613324C3 RU2014102924A RU2014102924A RU2613324C3 RU 2613324 C3 RU2613324 C3 RU 2613324C3 RU 2014102924 A RU2014102924 A RU 2014102924A RU 2014102924 A RU2014102924 A RU 2014102924A RU 2613324 C3 RU2613324 C3 RU 2613324C3
- Authority
- RU
- Russia
- Prior art keywords
- sialylation
- drug
- fsh
- patient
- total
- Prior art date
Links
- 230000002611 ovarian Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 8
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 8
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 230000009450 sialylation Effects 0.000 claims 4
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- -1 alkali metal cation Chemical class 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (3)
1. Применение фолликулостимулирующего гормона (ФСГ) в изготовлении лекарственного средства для лечения бесплодия у пациента, имеющего сывороточный уровень антимюллеровского гормона (АМГ) менее 15 пмоль/л, где лекарственное средство содержит суточную дозу, равную 12 мкг рекомбинантного ФСГ, причем указанный рекомбинантный ФСГ включает α2,3- и α2,6-сиалирование, где от 84,24 до 88,5% общего сиалирования представляет собой α2,3-сиалирование и от 11,5 до 15,76% общего сиалирования представляет собой α2,6-сиалирование.
2. Применение фолликулостимулирующего гормона (ФСГ) в изготовлении лекарственного средства для лечения бесплодия у пациента, имеющего сывороточный уровень антимюллеровского гормона (АМГ) не менее 15 пмоль/л, где лекарственное средство предназначено для введения в суточной дозе, равной от 0,10 до 0,19 мкг рекомбинантного ФСГ человеческого происхождения на кг массы тела пациента, причем указанный рекомбинантный ФСГ включает α2,3- и α2,6-сиалирование, где от 84,24 до 88,5% общего сиалирования представляет собой α2,3-сиалирование и от 11,5 до 15,76% общего сиалирования представляет собой α2,6-сиалирование.
3. Применение по п. 1 или 2, где лекарственное средство дополнительно содержит соль, содержащую фармацевтически приемлемый катион щелочного металла и представляющую собой соль Na+.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11176803 | 2011-08-08 | ||
| EP11176803.2 | 2011-08-08 | ||
| PCT/EP2012/065507 WO2013020996A1 (en) | 2011-08-08 | 2012-08-08 | Composition for controlled ovarian stimulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106756A Division RU2739037C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2014102924A RU2014102924A (ru) | 2015-09-20 |
| RU2613324C2 RU2613324C2 (ru) | 2017-03-15 |
| RU2613324C3 true RU2613324C3 (ru) | 2021-06-09 |
Family
ID=46785372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014102924A RU2613324C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
| RU2017106756A RU2739037C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017106756A RU2739037C3 (ru) | 2011-08-08 | 2012-08-08 | Композиция для контролируемой стимуляции яичников |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9694052B2 (ru) |
| EP (9) | EP2821080B1 (ru) |
| JP (5) | JP6161609B2 (ru) |
| KR (7) | KR102353144B1 (ru) |
| CN (2) | CN107281470A (ru) |
| AR (1) | AR087476A1 (ru) |
| AU (3) | AU2012293647B2 (ru) |
| BR (2) | BR112014002884A2 (ru) |
| CA (1) | CA2844282A1 (ru) |
| CY (1) | CY1117214T1 (ru) |
| DK (8) | DK3646881T3 (ru) |
| ES (7) | ES2884947T3 (ru) |
| FI (1) | FI3756681T3 (ru) |
| HK (2) | HK1204923A1 (ru) |
| HR (7) | HRP20230607T1 (ru) |
| HU (7) | HUE054312T2 (ru) |
| IL (2) | IL300380A (ru) |
| JO (1) | JO3092B1 (ru) |
| LT (7) | LT3646881T (ru) |
| MX (2) | MX348981B (ru) |
| PL (7) | PL3646881T3 (ru) |
| PT (6) | PT3195875T (ru) |
| RS (7) | RS61843B1 (ru) |
| RU (2) | RU2613324C3 (ru) |
| SA (1) | SA112330762B1 (ru) |
| SI (7) | SI3195875T1 (ru) |
| SM (1) | SMT201600038B (ru) |
| TR (2) | TR201900071T4 (ru) |
| TW (2) | TWI657822B (ru) |
| WO (1) | WO2013020996A1 (ru) |
| ZA (2) | ZA201400952B (ru) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
| EP3237608B1 (en) * | 2014-12-22 | 2019-10-09 | F. Hoffmann-La Roche AG | Cmp-dependent sialidase activity |
| WO2016166288A1 (en) * | 2015-04-17 | 2016-10-20 | Ferring B.V. | Composition for treatment of infertility |
| ES2770860T3 (es) | 2015-06-26 | 2020-07-03 | Ferring Bv | Métodos de purificación y/o inactivación viral |
| JP7255050B2 (ja) * | 2015-09-17 | 2023-04-11 | グアンジョウ・カントン・バイオロジクス・カンパニー・リミテッド | 安定性の増大した哺乳類卵胞刺激ホルモン組成物 |
| JP6982621B2 (ja) * | 2016-09-30 | 2021-12-17 | マイオバント サイエンシズ ゲーエムベーハー | 女性不妊の治療方法 |
| IL272763B2 (en) * | 2017-09-01 | 2024-02-01 | Ferring Bv | The composition for controlled stimulation of the ovary |
| JP2021522268A (ja) * | 2018-04-30 | 2021-08-30 | フェリング ベスローテン フェンノートシャップ | 制御された卵巣刺激のための組成物 |
| TW202027780A (zh) | 2018-10-17 | 2020-08-01 | 荷蘭商菲林公司 | 用於控制性卵巢刺激之組成物及方法 |
| US11576920B2 (en) | 2019-03-18 | 2023-02-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
| CN110841060A (zh) * | 2019-11-21 | 2020-02-28 | 上海交通大学 | Choriogonadotropin alfa在治疗多囊卵巢综合征中的应用 |
| TW202237173A (zh) | 2020-12-09 | 2022-10-01 | 荷蘭商菲林公司 | 用於受控的卵巢刺激之組成物及方法 |
| WO2023186331A1 (en) | 2022-04-01 | 2023-10-05 | Ferring B.V. | Mixed protocol for treatment of infertility |
| WO2023227761A1 (en) | 2022-05-26 | 2023-11-30 | Ferring B.V. | Compositions and methods for treatment of infertility in males |
| WO2024008971A1 (en) | 2022-07-08 | 2024-01-11 | Ferring B.V. | Compositions and methods for intrauterine insemination (iui) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL122732A0 (en) | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| EP1074265A1 (en) * | 1999-08-03 | 2001-02-07 | Erasmus Universiteit Rotterdam | Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility |
| DK1438336T3 (da) * | 2001-10-22 | 2006-10-02 | Applied Research Systems | Gonadotropiner til follikeldannelse |
| US20040248784A1 (en) * | 2003-06-03 | 2004-12-09 | Marco Filicori | Unitary combinations of FSH and hCG |
| US8501719B2 (en) * | 2005-11-08 | 2013-08-06 | American Infertility Of New York | Androgen treatment in females |
| TWI488640B (zh) * | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
| TWI604850B (zh) * | 2009-10-05 | 2017-11-11 | 菲瑞茵國際中心股份有限公司 | 藥學製劑 |
| EP2417982A1 (en) | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
| WO2012016576A1 (en) | 2010-08-04 | 2012-02-09 | Glycotope Gmbh | Improved recombinant human follicle-stimulating hormone |
| HUE025514T2 (en) * | 2010-09-29 | 2016-02-29 | Ferring Bv | Preparation for use in treating infertility |
| JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
-
2012
- 2012-07-18 JO JOP/2012/0197A patent/JO3092B1/ar active
- 2012-07-23 TW TW105124123A patent/TWI657822B/zh active
- 2012-07-23 TW TW101126453A patent/TWI555530B/zh active
- 2012-08-07 AR ARP120102883A patent/AR087476A1/es not_active Application Discontinuation
- 2012-08-07 SA SA112330762A patent/SA112330762B1/ar unknown
- 2012-08-08 BR BR112014002884A patent/BR112014002884A2/pt not_active Application Discontinuation
- 2012-08-08 DK DK19213649.7T patent/DK3646881T3/da active
- 2012-08-08 SI SI201231398T patent/SI3195875T1/sl unknown
- 2012-08-08 CN CN201710306350.4A patent/CN107281470A/zh active Pending
- 2012-08-08 DK DK19164277.6T patent/DK3566712T3/da active
- 2012-08-08 PL PL19213649T patent/PL3646881T3/pl unknown
- 2012-08-08 RS RS20210603A patent/RS61843B1/sr unknown
- 2012-08-08 PL PL20186935.1T patent/PL3756681T3/pl unknown
- 2012-08-08 KR KR1020217023662A patent/KR102353144B1/ko active IP Right Grant
- 2012-08-08 PL PL14184409T patent/PL2821080T3/pl unknown
- 2012-08-08 TR TR2019/00071T patent/TR201900071T4/tr unknown
- 2012-08-08 KR KR1020207029774A patent/KR20200121918A/ko not_active Application Discontinuation
- 2012-08-08 LT LTEP19213649.7T patent/LT3646881T/lt unknown
- 2012-08-08 LT LTEP21207717.6T patent/LT4005588T/lt unknown
- 2012-08-08 SI SI201231493T patent/SI2821080T1/sl unknown
- 2012-08-08 HU HUE19213649A patent/HUE054312T2/hu unknown
- 2012-08-08 ES ES19213649T patent/ES2884947T3/es active Active
- 2012-08-08 MX MX2014001489A patent/MX348981B/es active IP Right Grant
- 2012-08-08 ES ES18167552T patent/ES2742163T3/es active Active
- 2012-08-08 ES ES20186935T patent/ES2950911T3/es active Active
- 2012-08-08 PT PT17154031T patent/PT3195875T/pt unknown
- 2012-08-08 HU HUE19164277A patent/HUE053716T2/hu unknown
- 2012-08-08 HU HUE18167552 patent/HUE044610T2/hu unknown
- 2012-08-08 SI SI201232033T patent/SI3756681T1/sl unknown
- 2012-08-08 KR KR1020237004855A patent/KR20230024442A/ko not_active Application Discontinuation
- 2012-08-08 EP EP14184409.2A patent/EP2821080B1/en active Active
- 2012-08-08 PT PT201869351T patent/PT3756681T/pt unknown
- 2012-08-08 RU RU2014102924A patent/RU2613324C3/ru active Protection Beyond IP Right Term
- 2012-08-08 KR KR1020147005938A patent/KR102014469B1/ko active Protection Beyond IP Right Term
- 2012-08-08 DK DK14184409.2T patent/DK2821080T3/en active
- 2012-08-08 RS RS20181263A patent/RS57897B1/sr unknown
- 2012-08-08 JP JP2014524372A patent/JP6161609B2/ja active Active
- 2012-08-08 EP EP12753675.3A patent/EP2741763B1/en active Active
- 2012-08-08 PT PT212077176T patent/PT4005588T/pt unknown
- 2012-08-08 EP EP18167552.1A patent/EP3395357B1/en active Active
- 2012-08-08 LT LTEP18167552.1T patent/LT3395357T/lt unknown
- 2012-08-08 CN CN201280038831.7A patent/CN103732243A/zh active Pending
- 2012-08-08 RS RS20160080A patent/RS54561B1/en unknown
- 2012-08-08 RS RS20210425A patent/RS61672B1/sr unknown
- 2012-08-08 DK DK17154031.3T patent/DK3195875T3/en active
- 2012-08-08 PL PL12753675T patent/PL2741763T3/pl unknown
- 2012-08-08 EP EP19213649.7A patent/EP3646881B1/en active Active
- 2012-08-08 HU HUE14184409A patent/HUE041769T2/hu unknown
- 2012-08-08 DK DK21207717.6T patent/DK4005588T3/da active
- 2012-08-08 ES ES17154031.3T patent/ES2692774T3/es active Active
- 2012-08-08 PL PL17154031T patent/PL3195875T3/pl unknown
- 2012-08-08 EP EP20186935.1A patent/EP3756681B1/en active Active
- 2012-08-08 PT PT192136497T patent/PT3646881T/pt unknown
- 2012-08-08 LT LTEP20186935.1T patent/LT3756681T/lt unknown
- 2012-08-08 HU HUE17154031A patent/HUE040058T2/hu unknown
- 2012-08-08 PL PL19164277T patent/PL3566712T3/pl unknown
- 2012-08-08 KR KR1020217037512A patent/KR102499969B1/ko active IP Right Grant
- 2012-08-08 EP EP23208228.9A patent/EP4306174A3/en active Pending
- 2012-08-08 KR KR1020197024335A patent/KR102111514B1/ko active IP Right Grant
- 2012-08-08 SI SI201231653T patent/SI3395357T1/sl unknown
- 2012-08-08 KR KR1020197036505A patent/KR20190140098A/ko not_active IP Right Cessation
- 2012-08-08 EP EP17154031.3A patent/EP3195875B1/en active Active
- 2012-08-08 LT LTEP14184409.2T patent/LT2821080T/lt unknown
- 2012-08-08 LT LTEP19164277.6T patent/LT3566712T/lt unknown
- 2012-08-08 PT PT14184409T patent/PT2821080T/pt unknown
- 2012-08-08 PL PL18167552T patent/PL3395357T3/pl unknown
- 2012-08-08 TR TR2019/11269T patent/TR201911269T4/tr unknown
- 2012-08-08 SI SI201231921T patent/SI3646881T1/sl unknown
- 2012-08-08 HU HUE20186935A patent/HUE062640T2/hu unknown
- 2012-08-08 LT LTEP17154031.3T patent/LT3195875T/lt unknown
- 2012-08-08 SI SI201231884T patent/SI3566712T1/sl unknown
- 2012-08-08 DK DK20186935.1T patent/DK3756681T3/da active
- 2012-08-08 DK DK18167552.1T patent/DK3395357T3/da active
- 2012-08-08 IL IL300380A patent/IL300380A/en unknown
- 2012-08-08 WO PCT/EP2012/065507 patent/WO2013020996A1/en active Application Filing
- 2012-08-08 ES ES12753675.3T patent/ES2562648T3/es active Active
- 2012-08-08 DK DK12753675.3T patent/DK2741763T3/da active
- 2012-08-08 CA CA2844282A patent/CA2844282A1/en active Pending
- 2012-08-08 RU RU2017106756A patent/RU2739037C3/ru active Protection Beyond IP Right Term
- 2012-08-08 RS RS20190006A patent/RS58198B1/sr unknown
- 2012-08-08 AU AU2012293647A patent/AU2012293647B2/en active Active
- 2012-08-08 HR HRP20230607TT patent/HRP20230607T1/hr unknown
- 2012-08-08 RS RS20230518A patent/RS64328B1/sr unknown
- 2012-08-08 ES ES14184409T patent/ES2704878T3/es active Active
- 2012-08-08 FI FIEP20186935.1T patent/FI3756681T3/fi active
- 2012-08-08 BR BR122020001644-2A patent/BR122020001644B1/pt active IP Right Grant
- 2012-08-08 EP EP21207717.6A patent/EP4005588B1/en active Active
- 2012-08-08 RS RS20191038A patent/RS59107B1/sr unknown
- 2012-08-08 SI SI201230438T patent/SI2741763T1/sl unknown
- 2012-08-08 EP EP19164277.6A patent/EP3566712B1/en active Active
- 2012-08-08 ES ES19164277T patent/ES2871405T3/es active Active
- 2012-08-08 HU HUE12753675A patent/HUE027674T2/en unknown
- 2012-08-08 US US14/237,697 patent/US9694052B2/en active Active
- 2012-08-08 PT PT18167552T patent/PT3395357T/pt unknown
-
2014
- 2014-01-28 IL IL230696A patent/IL230696B2/en unknown
- 2014-02-06 MX MX2020010991A patent/MX2020010991A/es unknown
- 2014-02-07 ZA ZA2014/00952A patent/ZA201400952B/en unknown
- 2014-11-17 HK HK15105458.7A patent/HK1204923A1/xx unknown
- 2014-11-17 HK HK14111597.8A patent/HK1198005A1/zh unknown
-
2015
- 2015-09-01 ZA ZA2015/06382A patent/ZA201506382B/en unknown
-
2016
- 2016-02-09 HR HRP20160145TT patent/HRP20160145T1/hr unknown
- 2016-02-10 SM SM201600038T patent/SMT201600038B/it unknown
- 2016-02-18 CY CY20161100142T patent/CY1117214T1/el unknown
- 2016-12-15 AU AU2016273925A patent/AU2016273925B2/en active Active
-
2017
- 2017-03-16 JP JP2017051062A patent/JP6500050B2/ja active Active
- 2017-06-29 US US15/637,962 patent/US10624953B2/en active Active
-
2018
- 2018-05-09 AU AU2018203222A patent/AU2018203222B2/en active Active
- 2018-10-10 HR HRP20181639TT patent/HRP20181639T1/hr unknown
- 2018-12-27 JP JP2018243912A patent/JP6718951B2/ja active Active
-
2019
- 2019-01-03 HR HRP20190023TT patent/HRP20190023T1/hr unknown
- 2019-08-08 HR HRP20191437 patent/HRP20191437T1/hr unknown
-
2020
- 2020-04-17 US US16/851,260 patent/US11291708B2/en active Active
- 2020-06-15 JP JP2020102938A patent/JP7309660B2/ja active Active
-
2021
- 2021-02-18 HR HRP20210277TT patent/HRP20210277T1/hr unknown
- 2021-05-10 HR HRP20210722TT patent/HRP20210722T1/hr unknown
-
2022
- 2022-03-30 US US17/709,305 patent/US20220370567A1/en active Pending
-
2023
- 2023-07-05 JP JP2023110411A patent/JP2023134561A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2613324C3 (ru) | Композиция для контролируемой стимуляции яичников | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| RU2017123880A (ru) | Антагонисты миостатина или активина для лечения саркопении | |
| JP2014139220A5 (ru) | ||
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| JP2011225596A5 (ru) | ||
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| WO2009033665A3 (en) | Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP2011528333A5 (ru) | ||
| JP2017538705A5 (ru) | ||
| RU2013127420A (ru) | Способы уменьшения психогенного или компульсивного переедания | |
| RU2013137645A (ru) | Аналоги цистамина, применяемые для лечения болезни паркинсона | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| JP2014508758A5 (ru) | ||
| JP2014520874A5 (ru) | ||
| JP2019529569A5 (ru) | ||
| WO2009033666A3 (en) | Use of parathyroid hormone ( 1-34 ) as anti-hiv agent | |
| NZ710583A (en) | Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals | |
| JP2015524808A5 (ru) | ||
| JOP20190019A1 (ar) | تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH) | |
| MX2018013475A (es) | Acido carboxilico para tratar/prevenir congestion nasal. | |
| JP2016528283A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ND4A | Extension of patent duration |
Effective date: 20210609 |